MX2024005408A - Construcciones inmunogenicas y vacunas para ser utilizadas en el tratamiento profilactico y terapeutico de enfermedades causadas por sars-cov-2. - Google Patents

Construcciones inmunogenicas y vacunas para ser utilizadas en el tratamiento profilactico y terapeutico de enfermedades causadas por sars-cov-2.

Info

Publication number
MX2024005408A
MX2024005408A MX2024005408A MX2024005408A MX2024005408A MX 2024005408 A MX2024005408 A MX 2024005408A MX 2024005408 A MX2024005408 A MX 2024005408A MX 2024005408 A MX2024005408 A MX 2024005408A MX 2024005408 A MX2024005408 A MX 2024005408A
Authority
MX
Mexico
Prior art keywords
vaccines
cov
sars
prophylactic
therapeutic treatment
Prior art date
Application number
MX2024005408A
Other languages
English (en)
Spanish (es)
Inventor
Monika Sekelja
Gunnstein Norheim
Elisabeth Stubsrud
Agnete Fredriksen
Peter Ebert
Mark Klinger
Edward Osborne
Thomas Snyder
Original Assignee
Nykode Therapeutics ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nykode Therapeutics ASA filed Critical Nykode Therapeutics ASA
Publication of MX2024005408A publication Critical patent/MX2024005408A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C12N2770/20052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2024005408A 2021-11-03 2022-11-03 Construcciones inmunogenicas y vacunas para ser utilizadas en el tratamiento profilactico y terapeutico de enfermedades causadas por sars-cov-2. MX2024005408A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163275015P 2021-11-03 2021-11-03
US202263377087P 2022-09-26 2022-09-26
PCT/EP2022/080679 WO2023079001A1 (en) 2021-11-03 2022-11-03 Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2

Publications (1)

Publication Number Publication Date
MX2024005408A true MX2024005408A (es) 2024-08-06

Family

ID=84365420

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005408A MX2024005408A (es) 2021-11-03 2022-11-03 Construcciones inmunogenicas y vacunas para ser utilizadas en el tratamiento profilactico y terapeutico de enfermedades causadas por sars-cov-2.

Country Status (9)

Country Link
US (1) US20250049910A1 (cg-RX-API-DMAC10.html)
EP (1) EP4426344A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024540322A (cg-RX-API-DMAC10.html)
KR (1) KR20240110821A (cg-RX-API-DMAC10.html)
AU (1) AU2022381515A1 (cg-RX-API-DMAC10.html)
CA (1) CA3235174A1 (cg-RX-API-DMAC10.html)
IL (1) IL312539A (cg-RX-API-DMAC10.html)
MX (1) MX2024005408A (cg-RX-API-DMAC10.html)
WO (1) WO2023079001A1 (cg-RX-API-DMAC10.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004215489B2 (en) 2003-02-25 2010-07-15 Nykode Therapeutics ASA Modified antibody
WO2011161244A1 (en) 2010-06-25 2011-12-29 Vaccibody As Homodimeric protein constructs
EP3533462A1 (en) 2011-12-21 2019-09-04 Vaccibody AS Vaccines against hpv
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
CN113631185A (zh) 2019-02-27 2021-11-09 尼克塔治疗公司 用于治疗癌症的免疫治疗组合
PH12022552164A1 (en) * 2020-02-19 2023-11-29 United Biomedical Inc Designer peptides and proteins for the detection, prevention and treatment of coronavirus disease, 2019 (covid-19)
US20230218741A1 (en) * 2020-03-31 2023-07-13 The Children's Hospital Of Philadelphia Sars-cov-2 vaccines for population-scale immunity

Also Published As

Publication number Publication date
JP2024540322A (ja) 2024-10-31
WO2023079001A1 (en) 2023-05-11
AU2022381515A1 (en) 2024-05-09
CA3235174A1 (en) 2023-05-11
IL312539A (en) 2024-07-01
US20250049910A1 (en) 2025-02-13
KR20240110821A (ko) 2024-07-16
EP4426344A1 (en) 2024-09-11

Similar Documents

Publication Publication Date Title
MX2026002469A (es) Nuevas moleculas de acido nucleico artificiales
MX2021015753A (es) Constructo de arn.
MX2023003875A (es) Formulacion de una vacuna peptidica.
ZA202501799B (en) Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
BR112022005687A2 (pt) Vacinas contra o hbv e métodos para tratar o hbv
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
BRPI0610093A2 (pt) composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente
MX2018013640A (es) Liposomas pegiladas y metodos de uso.
MX392028B (es) Vacunas para el tratamiento y prevención del cáncer.
BR112018006074A2 (pt) vetores de fator viii de vírus adeno-associado, partículas virais associadas e formulações terapêuticas compreendendo as mesmas
CY1123011T1 (el) Θεραπευτικη χρηση οστικων μορφογενετικων πρωτεϊνων
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
CY1114716T1 (el) Ανασυσταθεντα επιφανειοδραστικα τα οποια διαθετουν βελτιωμενες ιδιοτητες
MX2022003758A (es) Composiciones para el cuidado bucal que comprenden acido beta de lupulo y aminoacido.
SA522431748B1 (ar) طرق لإنتاج أرجيناز 1 ناتج بمعاودة الارتباط الجيني بشري واستخداماته
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
AR101871A1 (es) Composiciones de glicoconjugado inmunogénico / terapéutico y sus usos
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
EA202090063A1 (ru) Композиции и способы для лечения таупатий
MX2023007228A (es) Constructo de arn.
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها
MX2023007229A (es) Constructo de arn.
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual
BR112023011605A2 (pt) Uso do peptídeo, método de tratamento de câncer ou infecções virais, e, combinação farmacêutica